VOOZH about

URL: https://pubmed.ncbi.nlm.nih.gov/36938325/

⇱ The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants - PubMed


Clipboard, Search History, and several other advanced features are temporarily unavailable.
Skip to main page content
👁 Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

👁 Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Abstract

As the fifth variant of concern of the SARS-CoV-2 virus, the Omicron variant (B.1.1.529) has quickly become the dominant type among the previous circulating variants worldwide. During the Omicron wave, several subvariants have emerged, with some exhibiting greater infectivity and immune evasion, accounting for their fast spread across many countries. Recently, two Omicron subvariants, BQ.1 and XBB lineages, including BQ.1.1, XBB.1, and XBB.1.5, have become a global public health issue given their ability to escape from therapeutic monoclonal antibodies and herd immunity induced by prior coronavirus disease 2019 (COVID-19) vaccines, boosters, and infection. In this respect, XBB.1.5, which has been established to harbor a rare mutation F486P, demonstrates superior transmissibility and immune escape ability compared to other subvariants and has emerged as the dominant strain in several countries. This review provides a comprehensive overview of the epidemiological features, spike mutations, and immune evasion of BQ.1 and XBB lineages. We expounded on the mechanisms underlying mutations and immune escape from neutralizing antibodies from vaccinated or convalescent COVID-19 individuals and therapeutic monoclonal antibodies (mAbs) and proposed strategies for prevention against BQ.1 and XBB sublineages.

Keywords: BQ.1 and XBB lineages; Omicron; XBB.1.5; immune escape.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interests.

Figures

👁 FIGURE 1
FIGURE 1
The estimated proportions of BQ.1 and XBB lineages. (A) and (B) show the proportions of the Omicron subvariants and other variants that moved every two weeks from 15 September, 2022 to 2 February, 2023 globally and in other three countries (Singapore, USA and UK). Data were obtained from GISAID and last accessed on 2 February 2023. (C) shows the global Re of BA.5, BQ.1, BQ.1.1, XBB, XBB.1 and XBB.1.5.
👁 FIGURE 2
FIGURE 2
Schematic diagram shows the spike mutations of BQ.1 (A) and XBB lineages (B), including their ancestral strains BA.5 and BA.2. The mutations of BA.2, BA.5, BQ.1, and XBB are obtained from Refs. [3, 8, 59], and last accessed on 20 January 2023.
👁 FIGURE 3
FIGURE 3
The superior transmissibility of BQ.1 and XBB lineages. New subvariants of the Omicron variant, BQ.1/BQ.1.1 and XBB/XBB.1/XBB.1.5, with substantial mutations, have contributed to the advantage in immune evasion and sharp increase in infectivity.

References

    1. WHO . WHO Coronavirus (COVID‐19) Dashboard. 2023. Accessed January 16, 2023. https://covid19.who.int/
    1. Uraki R, Ito M, Furusawa Y, et al. Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB. Lancet Infect Dis. 2023;23(1):30‐32. - PMC - PubMed
    1. Wang Q, Iketani S, Li Z, et al. Alarming antibody evasion properties of rising SARS‐CoV‐2 BQ and XBB subvariants. Cell. 2023;186(2):279‐286. - PMC - PubMed
    1. WHO . Tracking SARS‐CoV‐2 variants. 2023. Accessed January 16, 2023. https://www.who.int/activities/tracking‐SARS‐CoV‐2‐variants/tracking‐SAR...
    1. WHO . Statement on Omicron sublineages BQ.1 and XBB. 2023. Accessed January 16, 2023. https://www.who.int/news/item/27‐10‐2022‐tag‐ve‐statement‐on‐omicron‐sub...

LinkOut - more resources

Cite

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.